 |
|
|
| The Lp-PLA2 Studies Collaboration*SummaryBackground Lipoprotein-associated phospholipase A2 (Lp-PLA2), an inflammatory enzyme expressed in atheroscleroticplaques, is a therapeutic target being assessed in trials of vascular disease prevention. We investigated associations of circulating Lp-PLA2 mass and activity with risk of coronary heart disease, stroke, and mortality under different circumstances.Methods With use of individual records from 79 036 participants in 32 prospective studies (yielding 17 722 incident fatal or non-fatal outcomes during 474 976 person-years at risk), we did a meta-analysis of within-study regressions to calculate risk ratios (RRs) per 1 SD higher value of Lp-PLA2 or other risk factor. | ||
 |